MDGL Stock Down -16% after 7-Day Loss Streak
Madrigal Pharmaceuticals (MDGL) stock hit day 7 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -16% return. The company has lost about $1.0 Bil in value over the last 7 days, with its current market capitalization at about $6.5 Bil. The stock remains 4.7% below its value at the end of 2024. This compares with year-to-date returns of 8.6% for the S&P 500.
Comparing MDGL Stock Returns With The S&P 500
The following table summarizes the return for MDGL stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MDGL | S&P 500 |
|---|---|---|
| 1D | -1.4% | 0.0% |
| 7D (Current Streak) | -15.6% | 1.5% |
| 1M (21D) | -1.8% | 4.1% |
| 3M (63D) | -10.0% | 15.6% |
| YTD 2025 | -4.7% | 8.6% |
| 2024 | 33.4% | 23.3% |
| 2023 | -20.3% | 24.2% |
| 2022 | 242.5% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
- Cash Rich, Low Price – CDW Stock to Break Out?
- Years of Rewards: $34 Bil From Eli Lilly Stock
- Costco Wholesale Stock Capital Return Hits $20 Bil
- Arista Networks Stock Hits Key Support – Buying Opportunity?
- Humana Stock Near Crucial Support – Buy Signal?
- Booking Stock Delivers Strong Cash Yield – Upside Ahead?
There are currently 42 S&P constituents with 3 days or more of consecutive gains and 69 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 9 | 47 |
| 4D | 12 | 20 |
| 5D | 10 | 1 |
| 6D | 7 | 1 |
| 7D or more | 4 | 0 |
| Total >=3 D | 42 | 69 |
Key Financials for Madrigal Pharmaceuticals (MDGL)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $- | $180.1 Mil |
| Operating Income | $-380.5 Mil | $-497.9 Mil |
| Net Income | $-373.6 Mil | $-465.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $103.3 Mil | $137.3 Mil |
| Operating Income | $-67.0 Mil | $-79.3 Mil |
| Net Income | $-59.4 Mil | $-73.2 Mil |
The losing streak MDGL stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.